FN2 Earnings Intelligence
Intuitive Surgical, Inc. earnings overview
Latest Intuitive Surgical, Inc. (ISRG) earnings intelligence, including the newest scorecard, market reaction, and transcript analysis.
Intuitive Surgical, Inc.
The supplied analysis supports a constructive operating thesis: procedure growth, da Vinci 5 and SP adoption, Ion expansion, and new AI and imaging capabilities provide multiple growth drivers. The case is balanced by pricing pressure, China policy, reimbursement uncertainty, competition, and execution risk.
Intuitive Surgical, Inc.
Intuitive Surgical delivered another quarter of strong operational execution, with procedure volumes up 16% year-over-year and revenue rising 19% to $2.89 billion, driven by da Vinci 5, SP, and ION platform adoption. However, the guidance posture shifted from raised in Q1 to merely maintained in Q2, and the stock has since drifted approximately 10% below its event-session close. New initiatives -- an extended-use instrument program targeting H1 2027 commercialization and a GI robotic endoscope in FDA 510(k) review -- could expand addressable markets but also introduce uncertainty around per-procedure revenue economics. The non-GAAP gross margin outlook was nudged higher to 68-69% from 67.5-68.5%, a modest positive. The bullish score eased to 78 from 85 last quarter, reflecting the guidance plateau and new program questions. EPS of $2.80 beat consensus by 13% and revenue of $2.89…
Intuitive Surgical, Inc.
Reported results and management commentary support continued earnings growth. Q1 beat estimates on both top and bottom line, procedure volume grew 17% with single-port up 68%, and full-year guidance was raised, pointing to durable demand for the da Vinci 5 and SP platforms into next year. Counterweights are a roughly -7% post-earnings drift, China tender and pricing pressure, and Japan hospital financing constraints, so the bull case leans on sustained international and specialty expansion rather than near-term re-rating.
Intuitive Surgical, Inc.
The supplied analysis supports a constructive but conditional view: da Vinci 5 adoption, procedure growth, international expansion, ASC penetration, and digital services provide a credible growth path, but the case depends on execution, regulatory progress, margin discipline, and resilience to competitive and macro pressures.
Intuitive Surgical, Inc.
The latest analysis supports a constructive operating thesis: procedure growth, da Vinci V adoption, ION expansion, and international placements are reinforcing demand. The main test is whether utilization, margins, and capital placements remain resilient as the mix broadens and regional risks persist.
Intuitive Surgical, Inc.
The supplied analyses support a constructive operating trajectory for Intuitive Surgical: procedure growth, da Vinci 5 adoption, SP and Ion expansion, and international demand provide the growth case. That case is balanced by tariff, supply, regulatory, hospital-budget and Medicaid-related risks, while the event's negative abnormal market reaction shows that strong operating signals did not eliminate execution concerns.
Intuitive Surgical, Inc.
The supplied analysis supports a constructive operating outlook: resilient procedure demand, da Vinci 5 adoption and international growth are positive evidence, but tariff-related margin pressure, supply constraints and overseas capital budgets make the one-year growth case conditional rather than established.
Intuitive Surgical, Inc.
The supplied analysis supports a constructive but qualified view: da Vinci 5, Ion, SP, digital tools, and expanded indications provide growth drivers, while margin pressure, competition, tariffs, and regional capital constraints temper the outlook.
Get the ISRG recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.